Drug search by name

Idamycin and Hepatic dysfunction

Result of checking the interaction of drug Idamycin and disease Hepatic dysfunction for safety when used together.

Check result:

Idamycin <> Hepatic dysfunction

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Idarubicin undergoes extensive extrahepatic metabolism and is primarily eliminated by biliary excretion. The pharmacokinetic disposition of idarubicin has not been studied in leukemia patients with hepatic impairment. It is thought that the metabolism of idarubicin would be decreased in moderate to severe hepatic dysfunction and lead to increased systemic drug levels and toxicity. Therapy with idarubicin should be administered cautiously and dosage reduction considered in patients with compromised hepatic function. Idarubicin injection should not be administered if bilirubin level exceeds 5 mg %. Clinical monitoring of hepatic function is recommended prior to and during therapy.

References:

Petti MC, Mandelli F "Idarubicin in acute leukemias: experience of the Italian Cooperative Group GIMEMA." Semin Oncol 16 (1 Suppl) (1989): 10-5
Dodion P, Finet C, Crespeigne N, Beer M, Nicaise C, Rozencweig M, Kenis Y "Phase I study of oral idarubicin given with a weekly schedule." Invest New Drugs 4 (1986): 31-8
Chisesi T, Capnist G, de Dominicis E, Dini E "A phase II study of idarubicin (4-demethoxydaunorubicin) in advanced myeloma." Eur J Cancer Clin Oncol 24 (1988): 681-4
"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn, Kalamazoo, MI.
Daghestani AN, Arlin ZA, Leyland-Jones B, Gee TS, Kempin SJ, Mertelsmann R, Budman D, Schulman P, Baratz R, Williams L, et al "Phase I and II clinical and pharmacological study of 4- demethoxydaunorubicin (idarubicin) in adult patients with acute leukemia." Cancer Res 45 (1985): 1408-12
Krarup-Hansen A, Andersen E, Elbaek K, Rasmussen SN, Dalmark M "Phase I study of 4-demethoxydaunorubicin by oral route in patients with advanced cancer." Acta Oncol 27 (1988): 521-5
Lowenthal RM, Chesterman CN, Griffiths JD, Manoharan A, Harris MG, Herrmann RP, Rooney KF, Rozenberg MC, Salem HH, Wolf MM, et al "Oral idarubicin as single-agent treatment of acute nonlymphocytic leukemia in poor-risk patients." Cancer Treat Rep 71 (1987): 1279-81

Idamycin

Generic Name: idarubicin

Brand Name: Idamycin PFS, Idamycin

Synonyms: n.a.

What is Idamycin?